VTRS vs. SRPT, BGNE, TEVA, BMRN, RDY, UTHR, CTLT, ROIV, VKTX, and GMAB
Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Sarepta Therapeutics (SRPT), BeiGene (BGNE), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Catalent (CTLT), Roivant Sciences (ROIV), Viking Therapeutics (VKTX), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical preparations" industry.
Viatris (NASDAQ:VTRS) and Sarepta Therapeutics (NASDAQ:SRPT) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
Sarepta Therapeutics has a net margin of 1.20% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat Sarepta Therapeutics' return on equity.
Sarepta Therapeutics received 1404 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 75.40% of users gave Sarepta Therapeutics an outperform vote while only 35.59% of users gave Viatris an outperform vote.
Viatris has higher revenue and earnings than Sarepta Therapeutics. Viatris is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viatris had 10 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 16 mentions for Viatris and 6 mentions for Sarepta Therapeutics. Viatris' average media sentiment score of 0.29 beat Sarepta Therapeutics' score of 0.06 indicating that Viatris is being referred to more favorably in the media.
Viatris presently has a consensus price target of $11.00, indicating a potential downside of 3.17%. Sarepta Therapeutics has a consensus price target of $161.81, indicating a potential upside of 20.85%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sarepta Therapeutics is more favorable than Viatris.
79.9% of Viatris shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Viatris has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Summary
Sarepta Therapeutics beats Viatris on 11 of the 18 factors compared between the two stocks.
Get Viatris News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
